JC: Epistaxis – The NoPAC trial – Does TXA work?
Is Tranexamic Acid a useful adjunct in the management of epistaxis
JC: Epistaxis – The NoPAC trial – Does TXA work? Read More
dom3
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s
In arguably the most important therapeutic news of the pandemic since Dexamethasone, the RECOVERY trial investigators have revealed the initial results on the Tocilizumab arm of the trial showing a
JC: RECOVERY trial shows Tocilizumab effective for COVID19. St Emlyn’s Read More
JC: Canadian TIA risk score. St Emlyn’s
We see a lot of patients in the ED with a history of what sounds very much like a transient ischaemic event (TIA). By definition the patient will have had
JC: Canadian TIA risk score. St Emlyn’s Read More
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s
Hot on the heels of a terrific pun and blog post about the use of Tocilizumab, capturing all the intrigue, hope and caution with the potential use of this novel therapeutic
Tocilizumorelikeit? The latest data on Tocilizumab. St Emlyn’s Read More
JC: Lopinavir/Ritonavir in the treatment of COVID-19
We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine
JC: Lopinavir/Ritonavir in the treatment of COVID-19 Read More
JC: Azithromycin in patients hospitalised with COVID-19
As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were
JC: Azithromycin in patients hospitalised with COVID-19 Read More
The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s
A defining feature of the COVID-19 pandemic has been the wide spectrum of clinical presentations, ranging from asymptomatic viremia to life-threatening illness.1 Factors such as advancing age and co-morbid status have
The Emerging Evidence for a Genetic Susceptibility to Severe Covid-19. St Emlyn’s Read More
Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s
A core skill in emergency medicine is in the identification and classification of risk categories for the patients we see. For many conditions we have derived, validated and refined scoring
Risk stratification in the ED for COVID19 patients: The PRIEST study. St Emlyn’s Read More